|
John Stone
United Kingdom
1254 Posts |
 Posted - 02/23/2008 : 22:12:10
|
SUMMARY NEWS REPORT
HEP B VACCINE CAUSES MULTIPLE SCLEROSIS - 2005 PRESS RELEASE
_____________________________________________________________________
SUMMARY NEWS REPORT
French judges probe firms over vaccinations - Fri Feb 1, 2008 3:32am EST
PARIS, Jan 31 (Reuters) - French authorities have opened a formal investigation into two managers from drugs groups GlaxoSmithKline (GSK.L: Quote, Profile, Research) and Sanofi Pasteur. It is alleged the companies failed to disclose side effects of Hepatitis B vaccine. From 1994 to 1998, almost two thirds of the French population and almost all newborn babies were vaccinated against hepatitis B
_____________________________________________________________________
2) HEP B VACCINE CAUSES MULTIPLE SCLEROSIS - 2005 PRESS RELEASE
Multiple Sclerosis Risk to British Babies - Previously Concealed Evidence
UK PRESS ASSOCIATION NEWSWIRE/ROMEIKE
London, England & Versailles, France [27] September 2005/Romeike/
Strong scientific evidence confirms British infants will be exposed
to an unacceptably high risk of complications, including multiple
sclerosis, if the British Medical Association's (BMA's) recent
universal infant hepatitis B vaccine recommendation goes ahead.
Whilst other evidence is embargoed, Dr. Marc Girard, a specialist in
the side effects of drugs and commissioned as a medical expert by
French courts, has been able to publish a scientific review of the
unembargoed evidence of the vaccine's hazards (Autoimmun Rev 2005; 4:
96-100). Dr Girard shows that French health authorities suppress studies
demonstrating serious risks. France was the first country to implement
universal hepatitis B vaccination in 1994.
Legal and ethical concerns also arise over the BMA's recommendation
because those at high risk from the hepatitis B virus are not infants
but promiscuous adults engaging in unsafe sex and intravenous drug
abusers. There is no clear individual clinical benefit of universal
hepatitis B vaccination. The duration of any protective effect is
uncertain whereas the vaccination carries with it risks of numerous
chronic auto-immune disorders, including Guillain-Barre syndrome,
lupus, rheumatism, blood disorders and chronic fatigue. In contrast,
the BMA's 10th May 2005 press release stated children were at risk of
hepatitis B infection from:
* biting and shared toys
* shared toothbrushes and razors
* mother to child transmission during birth
Dr Girard said:
"The BMA's recommendation is a surprising and unexpected change of
heart given the scathing public scepticism in the British Medical
Journal in 1996 to a pharmaceutical company promotion advocating
universal infant hepatitis B vaccination (BMJ 1996; 313: 825). It is
all the more surprising because whilst the risk factors for babies
have changed little, there is now impressive evidence that for a
preventive measure, hepatitis B vaccine is remarkable for the
frequency, variety and severity of complications from its use. The
toxicity of this vaccine is so unusual that, even if crucial data are
regrettably concealed or covered by Court order, scientific evidence
is already far higher than normally needed to justify severe
restrictive measures."
In addition, just days ago (20 Sept, 2005) the European Medicines
Agency EMEA) announced the withdrawal of hepatitis B containing
Hexavac vaccine, claiming concerns over efficacy. Hexavac had 4 months
earlier been associated with sudden infant deaths (Zinka et al. Vaccine
2005 May 18). Hexavac combines hepatitis B vaccine virus with other
routine vaccine components. The EMEA's reasons for withdrawal are
questionable. Efficacy trials are normally performed before vaccines
are licensed.
Other research supporting Dr Girard's findings includes research on
UK data showing a 3.1 increase in the relative risk of multiple
sclerosis after hepatitis B vaccination (Neurology 2004; 63:838-42).
Clifford Miller, British lawyer, graduate physicist, co-author of a
recent peer reviewed critique of flawed medical evidential practice
and former university lecturer said:-
"British Doctors administering hepatitis B vaccine to infants could
face criminal prosecution if fully informed consent is not obtained.
Civil prosecution for damages is possible over 21 years later if the
injured survive as adults."
"English and European law requires the application of the precautionary
principle. With such strong scientific evidence of harm it is unclear
why the BMA's recommendation was made, nor why universal infant
hepatitis B vaccination is reportedly being considered by the UK Joint
Committee on Vaccination and Immunisation."
"This is not the first time the BMA has executed a spectacular `U'
turn. Up to 1987 they consistently recommended against mumps
vaccination. In 1988 that conflicted with new government policy and
the objection was quietly dropped. The BMA's links with the
pharmaceutical industry are also a concern. The next government
proposal in the pipeline is to vaccinate against chickenpox, the
mildest known of all routine childhood diseases and for which the UK
Department of Health has ready prepared stories claiming it is a
killer."
"The British public should be concerned their children's safety rests
with independent researchers from overseas who can face harassment,
obstruction and official vilification for their work."
In his new paper now in press and available on line (Med
Hypotheses, doi 10.1016/j.mehy.2005.08.012), Dr Girard and co-author
Y. Comenge review the various mechanisms likely to account for the
biological plausibility of auto-immune disorders such as
demyelinating diseases and other hazards of this vaccine.
Because of the significance and scope of these observations and related
cross- correlations, Dr. Girard suggests that even in high-endemic
countries, the risk/benefit ratio of this unusually toxic vaccine
must be carefully re-assessed. Regarding the health situation in
the UK, the conclusion not to vaccinate is obvious.
INFORMATION FOR EDITORS:
About Dr Marc Girard:-
Pharmaceutical Industry Consultant: Glaxo, Aventis & others
Court Appointed Expert: Includes Bayer/Baycol cholesterol drug
litigation
Medical Doctor: Qualified 1983, trained: Hopital des Enfants Malades,
Paris, France
Masters in Mathematics 1976: Universite d'Orsay, Paris, France
References Used in Press Release:-
"Multiple sclerosis and hepatitis B vaccination: Adding the credibility
of molecular biology to an unusual level of clinical and epidemiological
evidence" Comenge Y;
Girard M (Med Hypotheses, doi 10.1016/j.mehy.2005.08.012)
(Text available in electronic form on request.)
"Autoimmune hazards of hepatitis B vaccine" Girard M (Autoimmun Rev
2005; 4:96-100)
(Text available in electronic form on request.)
"BMA calls for universal childhood vaccination against hepatitis B"
Press Release (10 May 2005):
http://tinyurl.com/7ca6j
"Medicine and the media: Shire Hall Communications and the case for
hepatitis B immunisation" BMJ 1996;313:825 (28 September 1996):
http://bmj.bmjjournals.com/cgi/content/full/313/7060/825
"European Medicines Agency recommends suspension of Hexavac" Press
Release - 20th September 2005
http://www.emea.eu.int/pdfs/human/press/pr/29736905en.pdf
"Unexplained cases of sudden infant death shortly after hexavalent
vaccination." Zinka B, Rauch E, Buettner A, Rueff F, Penning R. -
Vaccine. 2005 May 18;
http://tinyurl.com/drm8g
"Recombinant hepatitis B vaccine and the risk of multiple sclerosis - A
prospective study" Hernan MA, Jick SS, Olek MJ, Jick H(Neurology 2004;
63:838-42).
"Flawed Evidence Denies Drug Victims Justice" - Press Release,
Romeike/PA
http://tinyurl.com/adk38
"On Evidence, Medical and Legal" Dr D W Miller, Clifford Miller: - 10;
03- 70. J AmPhys Surg -
http://www.jpands.org/vol10no3/miller.pdf
========== Contact information
Dr. Marc Girard
Address: 1 bd de la Republique 78000-Versailles (France)
Mobile phone: 00 33 6 82 94 54 62
E-Mail: agosgirard@free.fr
Telephone: 00 331 39670110
Fax : 00 331 396700111
Mr. Clifford G. Miller
Address: Burnhill Business Centre,
50 Burnhill Road,
Beckenham,
Kent BR3 3LA (UK)
Mobile: 00 44 7941-976021
E-Mail: mediapr@cliffordmiller.com
Telephone: 00 44 208 663 0044
Fax: 00 44 208 663 0011
###
Region NATIONAL
|
|
Hep B 2005: Press Release
